about
The clinically used poly(ADP-ribose) polymerase (PARP) inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.Early Inhibition of Fatty Acid Synthesis Reduces Generation of Memory Precursor Effector T Cells in Chronic Infection.AQX-1125, small molecule SHIP1 activator inhibits bleomycin-induced pulmonary fibrosis.Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats.3-Mercaptopyruvate sulfurtransferase supports endothelial cell angiogenesis and bioenergeticsThe re-emerging pathophysiological role of the cystathionine-β-synthase - hydrogen sulfide system in Down syndrome
P50
description
researcher
@en
wetenschapper
@nl
name
Csaba Szabó
@en
Csaba Szabó
@nl
type
label
Csaba Szabó
@en
Csaba Szabó
@nl
prefLabel
Csaba Szabó
@en
Csaba Szabó
@nl
P31
P496
0000-0003-3110-4235